BR112021017644A2 - Composições farmacêuticas contendo anticorpos anti-lingo-1 - Google Patents
Composições farmacêuticas contendo anticorpos anti-lingo-1Info
- Publication number
- BR112021017644A2 BR112021017644A2 BR112021017644A BR112021017644A BR112021017644A2 BR 112021017644 A2 BR112021017644 A2 BR 112021017644A2 BR 112021017644 A BR112021017644 A BR 112021017644A BR 112021017644 A BR112021017644 A BR 112021017644A BR 112021017644 A2 BR112021017644 A2 BR 112021017644A2
- Authority
- BR
- Brazil
- Prior art keywords
- lingo
- pharmaceutical compositions
- antibodies
- compositions containing
- containing anti
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Dermatology (AREA)
- Hospice & Palliative Care (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Psychiatry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Inorganic Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962816668P | 2019-03-11 | 2019-03-11 | |
| US201962817323P | 2019-03-12 | 2019-03-12 | |
| PCT/US2020/021842 WO2020185750A1 (en) | 2019-03-11 | 2020-03-10 | Pharmaceutical compositions containing anti-lingo-1 antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112021017644A2 true BR112021017644A2 (pt) | 2021-11-16 |
Family
ID=70190131
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112021017644A BR112021017644A2 (pt) | 2019-03-11 | 2020-03-10 | Composições farmacêuticas contendo anticorpos anti-lingo-1 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20220144945A1 (https=) |
| EP (1) | EP3938395A1 (https=) |
| JP (1) | JP2022524814A (https=) |
| KR (1) | KR20210136063A (https=) |
| CN (1) | CN113661179A (https=) |
| AU (1) | AU2020234943A1 (https=) |
| BR (1) | BR112021017644A2 (https=) |
| CA (1) | CA3133072A1 (https=) |
| IL (1) | IL286162A (https=) |
| MA (1) | MA55298A (https=) |
| MX (1) | MX2021010420A (https=) |
| TW (1) | TW202103732A (https=) |
| UY (1) | UY38605A (https=) |
| WO (1) | WO2020185750A1 (https=) |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4475196A (en) | 1981-03-06 | 1984-10-02 | Zor Clair G | Instrument for locating faults in aircraft passenger reading light and attendant call control system |
| US4447233A (en) | 1981-04-10 | 1984-05-08 | Parker-Hannifin Corporation | Medication infusion pump |
| US4439196A (en) | 1982-03-18 | 1984-03-27 | Merck & Co., Inc. | Osmotic drug delivery system |
| US4447224A (en) | 1982-09-20 | 1984-05-08 | Infusaid Corporation | Variable flow implantable infusion apparatus |
| US4487603A (en) | 1982-11-26 | 1984-12-11 | Cordis Corporation | Implantable microinfusion pump system |
| US4486194A (en) | 1983-06-08 | 1984-12-04 | James Ferrara | Therapeutic device for administering medicaments through the skin |
| US4596556A (en) | 1985-03-25 | 1986-06-24 | Bioject, Inc. | Hypodermic injection apparatus |
| US4941880A (en) | 1987-06-19 | 1990-07-17 | Bioject, Inc. | Pre-filled ampule and non-invasive hypodermic injection device assembly |
| US4790824A (en) | 1987-06-19 | 1988-12-13 | Bioject, Inc. | Non-invasive hypodermic injection device |
| US5312335A (en) | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
| US5064413A (en) | 1989-11-09 | 1991-11-12 | Bioject, Inc. | Needleless hypodermic injection device |
| US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
| DK0678122T3 (da) | 1993-01-12 | 2000-03-06 | Biogen Inc | Rekombinante anti-VLA4 antistofmolekyler |
| WO1994017828A2 (en) | 1993-02-09 | 1994-08-18 | Biogen, Inc. | Treatment for insulin dependent diabetes |
| US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
| US5840299A (en) | 1994-01-25 | 1998-11-24 | Athena Neurosciences, Inc. | Humanized antibodies against leukocyte adhesion molecule VLA-4 |
| WO2004085648A2 (en) | 2003-03-19 | 2004-10-07 | Biogen Idec Ma Inc. | Nogo receptor binding protein |
| PT1776136E (pt) | 2004-06-24 | 2012-12-05 | Biogen Idec Inc | Tratamento de estados que envolvem desmielinização |
| PE20091174A1 (es) * | 2007-12-27 | 2009-08-03 | Chugai Pharmaceutical Co Ltd | Formulacion liquida con contenido de alta concentracion de anticuerpo |
| WO2010062896A1 (en) * | 2008-11-28 | 2010-06-03 | Abbott Laboratories | Stable antibody compositions and methods for stabilizing same |
| JP7149257B2 (ja) * | 2016-07-13 | 2022-10-06 | バイオジェン・エムエイ・インコーポレイテッド | Ｌｉｎｇｏ－１アンタゴニストの投与計画及び脱髄障害の処置のための使用 |
| AU2018263868A1 (en) * | 2017-05-02 | 2019-12-12 | Merck Sharp & Dohme Llc | Formulations of anti-LAG3 antibodies and co-formulations of anti-LAG3 antibodies and anti-PD-1 antibodies |
| IL272773B2 (en) * | 2017-08-22 | 2024-06-01 | Biogen Ma Inc | Pharmaceutical preparations containing anti-amyloid cell antibodies |
-
2020
- 2020-03-10 BR BR112021017644A patent/BR112021017644A2/pt not_active Application Discontinuation
- 2020-03-10 KR KR1020217031856A patent/KR20210136063A/ko not_active Withdrawn
- 2020-03-10 MA MA055298A patent/MA55298A/fr unknown
- 2020-03-10 EP EP20717406.1A patent/EP3938395A1/en not_active Withdrawn
- 2020-03-10 US US17/437,634 patent/US20220144945A1/en not_active Abandoned
- 2020-03-10 CN CN202080027211.8A patent/CN113661179A/zh active Pending
- 2020-03-10 TW TW109107890A patent/TW202103732A/zh unknown
- 2020-03-10 UY UY0001038605A patent/UY38605A/es not_active Application Discontinuation
- 2020-03-10 JP JP2021554699A patent/JP2022524814A/ja active Pending
- 2020-03-10 AU AU2020234943A patent/AU2020234943A1/en not_active Abandoned
- 2020-03-10 CA CA3133072A patent/CA3133072A1/en active Pending
- 2020-03-10 MX MX2021010420A patent/MX2021010420A/es unknown
- 2020-03-10 WO PCT/US2020/021842 patent/WO2020185750A1/en not_active Ceased
-
2021
- 2021-09-05 IL IL286162A patent/IL286162A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20220144945A1 (en) | 2022-05-12 |
| AU2020234943A1 (en) | 2021-09-23 |
| KR20210136063A (ko) | 2021-11-16 |
| MX2021010420A (es) | 2021-11-12 |
| UY38605A (es) | 2020-09-30 |
| WO2020185750A1 (en) | 2020-09-17 |
| JP2022524814A (ja) | 2022-05-10 |
| MA55298A (fr) | 2022-01-19 |
| CN113661179A (zh) | 2021-11-16 |
| IL286162A (en) | 2021-10-31 |
| CA3133072A1 (en) | 2020-09-17 |
| EP3938395A1 (en) | 2022-01-19 |
| TW202103732A (zh) | 2021-02-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2025003876A (es) | Compuestos para el tratamiento de enfermedades mediadas por alfa-1 antitripsina | |
| MX2022015257A (es) | Proteinas f de prefusion del virus respiratorio sincicial (vrs) solubles y estabilizadas. | |
| MX2020007898A (es) | Moduladores de cinasa de proteina asociada con rho. | |
| PH12020551019A1 (en) | IL-22 Fc FUSION PROTEINS AND METHODS OF USE | |
| MA43335B1 (fr) | Compositions d'arni de transthyrétine (ttr) et procédés pour les utiliser pour le traitement ou la prévention de maladies associées à ttr | |
| BR112022020753A2 (pt) | Compostos de ligação a tau | |
| BR112018011975A2 (pt) | composições úteis no tratamento de atrofia muscular espinhal | |
| EA201491646A1 (ru) | Аналоги антибиотика ариломицина широкого действия | |
| BR112021015616A2 (pt) | Ligantes de pseudoquinase tyk2 | |
| BR112018013084A2 (pt) | tratamentos de combinação compreendendo a administração de imidazopirazinonas | |
| BR112022021743A2 (pt) | Compostos e métodos direcionando a interleucina-34 | |
| BR112021022380A2 (pt) | Inibidores de jak | |
| NZ783377A (en) | Pegylated novel molecules for agonising tlr2 | |
| MX2020006328A (es) | Composición inmunogénica. | |
| MX2022015966A (es) | Anticuerpos y metodos para tratar enfermedades asociadas a claudina. | |
| CY1120501T1 (el) | Προερχομενα απο εζρινη πεπτιδια και φαρμακευτικες συνθεσεις αυτων | |
| ZA202202180B (en) | Engineered hcv e2 immunogens and related vaccine compositions | |
| EP4424373A3 (en) | Pharmaceutical compositions containing doravirine, tenofovir disoproxil fumarate and lamivudine | |
| BR112021017644A2 (pt) | Composições farmacêuticas contendo anticorpos anti-lingo-1 | |
| BR112022024853A2 (pt) | Processo para purificar uma mistura de dióis | |
| BR112022005608A2 (pt) | Inibidores de jak | |
| AR118304A1 (es) | Composiciones farmacéuticas que contienen anticuerpos anti-lingo-1 | |
| BR112022002390A2 (pt) | Inibidores de jak | |
| DE602005007471D1 (de) | Satraplatin zur behandlung von resistenten oder refrkatären tumoren | |
| BR112022018731A2 (pt) | Uso de um derivado de tienopiridona no tratamento de adrenoleucodistrofia ou adrenomieloneuropatia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
| B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |